RWD102 ASSESSING THE COST-UTILITY OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE TREATMENT AND THE NEED FOR REAL-WORLD EVIDENCE: A SINGAPORE PERSPECTIVE
RWD102 ASSESSING THE COST-UTILITY OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE TREATMENT AND THE NEED FOR REAL-WORLD EVIDENCE: A SINGAPORE PERSPECTIVE is a paper indexed in ScholarIQ from OpenAlex.
How many citations does RWD102 ASSESSING THE COST-UTILITY OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE TREATMENT AND THE NEED FOR REAL-WORLD EVIDENCE: A SINGAPORE PERSPECTIVE have?
RWD102 ASSESSING THE COST-UTILITY OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE TREATMENT AND THE NEED FOR REAL-WORLD EVIDENCE: A SINGAPORE PERSPECTIVE has 0 citations in the OpenAlex counts ScholarIQ stores.
When was RWD102 ASSESSING THE COST-UTILITY OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE TREATMENT AND THE NEED FOR REAL-WORLD EVIDENCE: A SINGAPORE PERSPECTIVE published?
RWD102 ASSESSING THE COST-UTILITY OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE TREATMENT AND THE NEED FOR REAL-WORLD EVIDENCE: A SINGAPORE PERSPECTIVE has 2025 year in the ScholarIQ index.
What is the open-access status of RWD102 ASSESSING THE COST-UTILITY OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE TREATMENT AND THE NEED FOR REAL-WORLD EVIDENCE: A SINGAPORE PERSPECTIVE?
RWD102 ASSESSING THE COST-UTILITY OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE TREATMENT AND THE NEED FOR REAL-WORLD EVIDENCE: A SINGAPORE PERSPECTIVE has hybrid oa status in the ScholarIQ index.
What is the DOI of RWD102 ASSESSING THE COST-UTILITY OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE TREATMENT AND THE NEED FOR REAL-WORLD EVIDENCE: A SINGAPORE PERSPECTIVE?
The DOI for RWD102 ASSESSING THE COST-UTILITY OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE TREATMENT AND THE NEED FOR REAL-WORLD EVIDENCE: A SINGAPORE PERSPECTIVE is on the source record.
What is the OpenAlex record for RWD102 ASSESSING THE COST-UTILITY OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE TREATMENT AND THE NEED FOR REAL-WORLD EVIDENCE: A SINGAPORE PERSPECTIVE?
The OpenAlex for RWD102 ASSESSING THE COST-UTILITY OF LECANEMAB FOR EARLY ALZHEIMER'S DISEASE TREATMENT AND THE NEED FOR REAL-WORLD EVIDENCE: A SINGAPORE PERSPECTIVE is on the source record.